ArticleAntimicrobial agents and chemotherapy2015
Genomic analysis of reduced susceptibility to tigecycline in Enterococcus faecium.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 79 citations in OpenAlex.
- Stepwise evolution of tigecycline resistance in Enterococcus hirae through early IS1216E-mediated tet(L) amplification and subsequent rpsJ mutations.Veterinary research · 2026Article
- Antimicrobial Resistance in Major Gram-Positive Pathogens: Beyond the Vancomycin Border.Antibiotics (Basel, Switzerland) · 2026Review
- Putative mutations associated with tetracycline resistance detected in Treponema spp.: an analysis of 4,355 Spirochaetales genomes.Access microbiology · 2025Article
- Unravelling Antimicrobial Resistance inVeterinary sciences · 2024Review
- Non-Clinical microbiology reviews · 2024Review
- Characterization of a Tigecycline-, Linezolid- and Vancomycin-Resistant Clinical Enteroccoccus faecium Isolate, Carrying vanA and vanB Genes.Infectious diseases and therapy · 2023Article
- Tigecycline Resistance-Associated Mutations in the MepA Efflux Pump in Staphylococcus aureus.Microbiology spectrum · 2023Article
- Dissemination and prevalence of plasmid-mediated high-level tigecycline resistance geneFrontiers in microbiology · 2022Review
- Evaluation of bactericidal effects of silver hydrosol nanotherapeutics againstFrontiers in cellular and infection microbiology · 2022Article
- Effects of Ribosomal Protein S10 Flexible Loop Mutations on Tetracycline and Tigecycline Susceptibility ofFrontiers in microbiology · 2021Article
- Resistance in Vancomycin-Resistant Enterococci.Infectious disease clinics of North America · 2020Review
- Article
- Mechanism of Eravacycline Resistance in ClinicalFrontiers in microbiology · 2020Article
- Biocide-Tolerant Listeria monocytogenes Isolates from German Food Production Plants Do Not Show Cross-Resistance to Clinically Relevant Antibiotics.Applied and environmental microbiology · 2019Article
- Pathogenicity of Enterococci.Microbiology spectrum · 2019Review
- Emergence of an Australian-like pstS-null vancomycin resistant Enterococcus faecium clone in Scotland.PloS one · 2019Article
- Molecular basis for the emergence of a new hospital endemic tigecycline-resistant Enterococcus faecalis ST103 lineage.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2019Article
- Antimicrobial susceptibility amongInfection and drug resistance · 2019Article
- Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance.BMC microbiology · 2018Article
- Resistance in In Vitro Selected Tigecycline-Resistant Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Is Driven by Mutations in mepR and mepA Genes.Microbial drug resistance (Larchmont, N.Y.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tigecycline (TIG) is approved for use for the treatment of complicated intra-abdominal infections, skin and skin structure infections, as well as pneumonia. Acquired resistance or reduced susceptibility to TIG has been observed in Gram-negative rods, has seldom been reported in Gram-positive organisms, and has not yet been reported in Enterococcus faecium. Using the serial passage method, in vitro mutant AusTig and in vitro mutants HMtig1 and HMtig2 with decreased TIG susceptibility (MICs, 0.25 μg/ml) were obtained from strains E. faecium Aus0004 and HM1070 (MICs, 0.03 μg/ml), respectively. In addition, two vancomycin-resistant E. faecium clinical isolates (EF16 and EF22) with reduced susceptibility to TIG (MICs, 0.5 and 0.25 μg/ml, respectively) were studied. Compared to the wild-type strains, the in vitro mutants also showed an increase in the MICs of other tetracyclines. An efflux mechanism did not seem to be involved in the reduced TIG susceptibility, since the presence of efflux pump inhibitors (reserpine or pantoprazole) did not affect the MICs of TIG. Whole-genome sequencing of AusTig was carried out, and genomic comparison with the Aus0004 genome was performed. Four modifications leading to an amino acid substitution were found. These mutations affected the rpsJ gene (efau004_00094, coding for the S10 protein of the 30S ribosomal subunit), efau004_01228 (encoding a cation transporter), efau004_01636 (coding for a hypothetical protein), and efau004_02455 (encoding the l-lactate oxidase). The four other strains exhibiting reduced TIG susceptibility were screened for the candidate mutations. This analysis revealed that three of them showed an amino acid substitution in the same region of the RpsJ protein. In this study, we characterized for the first time genetic determinants linked to reduced TIG susceptibility in enterococci.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.